VEGF Cancer Research Results

VEGF, Vascular endothelial growth factor: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
A signal protein produced by many cells that stimulates the formation of blood vessels. Vascular endothelial growth factor (VEGF) is a signal protein that plays a crucial role in angiogenesis, the process by which new blood vessels form from existing ones. This process is vital for normal physiological functions, such as wound healing and the menstrual cycle, but it is also a key factor in the growth and spread of tumors in cancer.
Because of its significant role in tumor growth and progression, VEGF has become a target for cancer therapies. Anti-VEGF therapies, such as monoclonal antibodies (e.g., bevacizumab) and small molecule inhibitors, aim to inhibit the action of VEGF, thereby reducing blood supply to tumors and limiting their growth. These therapies have been used in various types of cancer, including colorectal, lung, and breast cancer.
Scientific Papers found: Click to Expand⟱
5115- JG,    Natural Products to Fight Cancer: A Focus on Juglans regia
- Review, Var, NA
Casp3↑, Casp9↑, MMP↓, AR↓, PSA↓, E-cadherin↑, N-cadherin↓, Vim↓, Akt↓, GSK‐3β↓, EMT↑, TumCI↓, MMP9↓, VEGF↓, MMP2↓, TumCCA↑, ROS↑, Apoptosis↑, GSH↓, Catalase↓, SOD↓, GPx↓, DNAdam↑, γH2AX↑, eff↑, BAX↑, Fas↑, Pin1↓,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
3267- Lyco,    Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways
- in-vitro, Nor, HUVECs
*VEGF↓, *MMP2↓, *uPA↓, *Rac1↑, *TIMP2↑, *p38↓, *Akt↓, *angioG↓,
1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,
4782- Lyco,    New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, TumCI↓, TumCA↓, ROS↓, MMP2↓, MMP7↓, MMP9↓, VEGF↓, E-cadherin↑, TIMP1↑, TIMP2↑, BioAv↝, *IL12↓, *TNF-α↓, *IL1↓, *IL1β↓, *IL6↓, COX2↓, iNOS↓, *radioP↑, NF-kB↓, survivin↓, Casp3↑, Bax:Bcl2↑,
4516- MAG,    Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models
- in-vivo, NSCLC, NA
selectivity↑, Apoptosis↑, TumCCA↑, Casp3↑, cycD1/CCND1↓, CDK4↓, VEGF↓, FOXP3↓, IDO1↓,
4519- MAG,    Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer
- Review, Var, NA
*antiOx↑, *Inflam↓, *Bacteria↓, *AntiAg↑, *BBB↑, *BioAv↓, BAD↑, Casp3↑, Casp6↑, Casp9↑, JNK↑, Bcl-xL↓, PTEN↑, Akt↓, NF-kB↓, MMP7↓, MMP9↓, uPA↓, Hif1a↓, VEGF↓, FOXO3↓, Ca+2↑, TumCCA↑, ROS↑, Cyt‑c↑,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24/HTB-9
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31↓, CA↓,
2500- meben,    Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
- in-vitro, GBM, U87MG - in-vivo, GBM, NA
α-tubulin↓, AntiCan↑, TumCG↓, OS↑, VEGF↓, Hif1a↓,
1776- MEL,    Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis
- Review, NA, NA
Remission↑, OS↑, neuroP↑, VEGF↓, KISS1↑, TumCP↓, ChemoSideEff↓, radioP↑, Dose∅, *ROS↓, DNArepair↑, ROS↑,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
971- MEL,    Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
Hif1a↓, VEGF↓, p‑p70S6↓,
2487- metroC,    Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
- Review, HCC, NA
toxicity↓, toxicity↓, eff↝, angioG↓, CSCs↓, TSP-1↑, Hif1a↓, VEGF↓, eff↑,
2243- MF,    Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study
- in-vitro, Nor, NA
*eff↑, *mTOR↑, *Akt↑, *PKA↑, *MAPK↑, *ERK↑, *BMP2↑, *Diff↑, *PKCδ↓, *VEGF↑, *IL10↑,
4111- MF,    Coupling of pulsed electromagnetic fields (PEMF) therapy to molecular grounds of the cell
- Review, Arthritis, NA
*Inflam↓, *Cartilage↑, *Pain↓, *QoL↑, *Dose↝, *VEGF↑, *NO↑, *TGF-β↑, *MMP9↓, *PGE2↑, *GPx3↑, *SOD2↑, *Catalase↑, *GSR↑, *Ca+2↑,
4150- MF,    Enhanced effect of combining bone marrow mesenchymal stem cells (BMMSCs) and pulsed electromagnetic fields (PEMF) to promote recovery after spinal cord injury in mice
- in-vitro, NA, NA
*BDNF↑, *VEGF↑,
3536- MF,    Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis
- Review, Arthritis, NA - Review, Stroke, NA
*Inflam↓, *Diff↑, *toxicity∅, *other↑, *SOX9↑, *COL2A1↑, *NO↓, *PGE2↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *IL6↓, *IL10↑, *angioG↑, *MSCs↑, *VEGF↑, *TGF-β↑, *angioG↝, *VEGF↓, Ca+2↝,
3480- MF,    Cellular and Molecular Effects of Magnetic Fields
- Review, NA, NA
ROS↑, *Ca+2↑, *Inflam↓, *Akt↓, *mTOR↓, selectivity↑, *memory↑, *MMPs↑, *VEGF↑, *FGF↑, *PDGF↑, *TNF-α↑, *HGF/c-Met↑, *IL1↑,
3479- MF,    Evaluation of Pulsed Electromagnetic Field Effects: A Systematic Review and Meta-Analysis on Highlights of Two Decades of Research In Vitro Studies
- Review, NA, NA
*eff↓, eff↝, *Hif1a↑, *VEGF↑, *TIMP1↑, *E2Fs↑, *MMP2↑, *MMP9↑, Apoptosis↑,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
3477- MF,    Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis
- Review, NA, NA
*Ca+2↑, *VEGF↑, *angioG↑, Ca+2↑, ROS↑, Necroptosis↑, TumCCA↑, Apoptosis↑, *ATP↑, *FAK↑, *Wnt↑, *β-catenin/ZEB1↑, *ROS↑, p38↑, MAPK↑, β-catenin/ZEB1↓, CSCs↓, TumCP↓, ROS↑, RadioS↑, Ca+2↑, eff↓, NO↑,
3476- MF,    Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation
- in-vitro, Stroke, 1321N1 - in-vitro, Park, NA
*VEGF↑, *eff↑, *neuroP↑, *other↑, *eff↑, *Inflam↓, *Hif1a∅,
3482- MF,    Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice
- in-vitro, NA, NA
*cardioP↑, *VEGF↑, *VEGFR2↑, *Hif1a↑, *FGF↑, *ITGB1↑, *angioG↑,
3501- MF,    Unveiling the Power of Magnetic-Driven Regenerative Medicine: Bone Regeneration and Functional Reconstruction
- Review, NA, NA
*VEGF↑, *BMPs↓, *SMAD4↑, *SMAD5↑, *Ca+2↑,
499- MF,    The Effect of Pulsed Electromagnetic Fields on Angiogenesis
- Review, NA, NA
angioG↑, VEGF↑, VGCC↑,
194- MF,    Electromagnetic Field as a Treatment for Cerebral Ischemic Stroke
- Review, Stroke, NA
*BAD↓, *BAX↓, *Casp3↓, *Bcl-xL↑, *p‑Akt↑, *MMP9↓, *p‑ERK↑, *HIF-1↓, *ROS↓, *VEGF↑, *Ca+2↓, *SOD↑, *IL2↑, *p38↑, *HSP70/HSPA5↑, *Apoptosis↓, *ROS↓, *NO↓,
5241- MF,    A review on the use of magnetic fields and ultrasound for non-invasive cancer treatment
- Review, Var, NA
other↑, BloodF↑, Glycolysis↓, ATP↓, VEGF↓, ROS↑, P-gp↓, Apoptosis↑, selectivity↑, Ca+2↑, Catalase↑,
1203- MSM,    Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways
- vitro+vivo, BC, MDA-MB-231
tumCV↓, STAT3↓, STAT5↓, IGF-1↓, Hif1a↓, VEGF↓, Brk/PTK6↓, IGF-1R↓,
3847- MSM,    Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement
- Review, Arthritis, NA
*Inflam↓, *Pain↓, *ROS↓, *antiOx↑, *Dose↝, *Half-Life↝, *NF-kB↓, *IL1↓, *IL6↓, *TNF-α↓, *iNOS↓, *COX2↓, *NLRP3↓, *NRF2↑, *STAT↓, *Cartilage↑, *eff↑, *eff↑, *GSH↑, *uricA↓, tumCV↓, TumCCA↑, necrosis↑, Apoptosis↑, VEGF↓, HSP90↓, IGF-1?,
930- MushShi,    Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation
- in-vitro, Ovarian, NA
p‑STAT3↓, PTPN6↑, cycD1/CCND1↓, Bcl-2↓, Mcl-1↓, survivin↓, VEGF↓,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1/CCND1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
4225- NarG,    Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury
- in-vivo, NA, NA
*motorD↑, *BDNF↑, *VEGF↑, *Bax:Bcl2↓, *Casp3↓, *Apoptosis↓, *eff↑,
1270- NCL,  Rad,    Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells
- in-vivo, Lung, NA
Hif1a↓, VEGF↓,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
959- PACs,    Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression
- in-vitro, GBM, U251 - in-vitro, BC, MDA-MB-231
Hif1a↓, p‑Akt↓, p‑S6K↓, p‑S6↓, VEGF↓,
2064- PB,  Rad,    Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
Bcl-xL↓, Cav1↓, VEGF↓, RadioS↑, chemoP↑, HDAC↓, *toxicity↓, Diff↑, Prot↓,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
1673- PBG,    An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, MALAT1↓, P53↑, RadioS↑, OS↑, ROS↑, NF-kB↓, p65↑, MMP↓, ROS↑, MMP9↓, β-catenin/ZEB1↓, Vim↓, E-cadherin↓, VEGF↓, EMT↓,
1660- PBG,    Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents
- Review, Var, NA
MMPs↓, angioG↓, TumMeta↓, TumCCA↑, Apoptosis↑, ChemoSideEff↓, eff∅, HDAC↓, PTEN↑, p‑PTEN↓, p‑Akt↓, Casp3↑, p‑ERK↑, p‑FAK↑, Dose?, Akt↓, GSK‐3β↓, FOXO3↓, eff↑, IL2↑, IL10↑, NF-kB↓, VEGF↓, mtDam↑, ER Stress↑, AST↓, ALAT↓, ALP↓, COX2↓, eff↑, Bax:Bcl2↑,
1662- PBG,    The immunomodulatory and anticancer properties of propolis
- Review, Var, NA
IL6↓, IL12↓, IL10↑, CSCs↓, PAK1↓, VEGF↓, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, ChemoSen↑, RadioS↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
1668- PBG,    Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms
- Review, Var, NA
antiOx↑, Inflam↓, AntiCan↑, TumCP↓, Apoptosis↑, eff↝, MMPs↓, TNF-α↓, iNOS↓, COX2↓, IL1β↑, *BioAv↓, BAX↑, Casp3↑, Cyt‑c↑, Bcl-2↓, eff↑, selectivity↑, P53↑, ROS↑, Casp↑, eff↑, ERK↓, Dose∅, TRAIL↑, NF-kB↑, ROS↑, Dose↑, MMP↓, DNAdam↑, TumAuto↑, LC3II↑, p62↓, EGF↓, Hif1a↓, VEGF↓, TLR4↓, GSK‐3β↓, NF-kB↓, Telomerase↓, ChemoSen↑, ChemoSideEff↓,
3259- PBG,    Propolis and its therapeutic effects on renal diseases: A review
- Review, Nor, NA
*Inflam↓, *COX2↓, *ROS↓, *NO↓, *NF-kB↓, TumCP↓, angioG↓, VEGF↓, STAT↓, Hif1a↓, RenoP↑, TLR4↓, *MDA↓, *GSH↑, *SOD↑, *Catalase↑, *toxicity∅,
4930- PEITC,    Targeted anti-cancer therapy: Co-delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy
- vitro+vivo, Lung, A549
VEGF↓, Hif1a↓, TumCG↓, TumCP↓,
4939- PEITC,    Phenethyl Isothiocyanate Inhibits Angiogenesis In vitro and Ex vivo
- in-vitro, Pca, PC3 - ex-vivo, Nor, HUVECs
Risk↓, angioG↓, VEGF↓, TumCMig↓, Akt↓, EGF↓, TumCMig↓,

Showing Research Papers: 201 to 250 of 329
Prev Page 5 of 7 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 329

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   antiOx⇅, 1,   Catalase↓, 4,   Catalase↑, 2,   CYP1A1↓, 2,   CYP1A1↑, 1,   GPx↓, 2,   GPx↑, 2,   GSH↓, 4,   GSH↑, 1,   GSR↓, 1,   GSTs↓, 1,   H2O2↓, 1,   HO-1↓, 2,   HO-1↑, 1,   lipid-P↓, 2,   MDA↓, 1,   NOX4↑, 1,   NQO1↓, 1,   NRF2↓, 3,   NRF2↑, 2,   ROS↓, 3,   ROS↑, 24,   ROS⇅, 1,   SIRT3↓, 1,   SIRT3↑, 1,   SOD↓, 3,   SOD↑, 1,   SOD2↓, 2,   Trx1↑, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   CDC2↓, 2,   EGF↓, 3,   MEK↓, 1,   MKK4↓, 1,   MMP↓, 5,   mtDam↑, 1,   Raf↓, 1,   e-Raf↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   CAIX↑, 1,   Cav1↓, 1,   p‑cMyc↑, 1,   FASN↓, 2,   GLO-I↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   IDO1↓, 1,   lactateProd↓, 1,   PPARγ↑, 2,   p‑S6↓, 1,   p‑S6K↓, 1,   SIRT1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 11,   p‑Akt↓, 6,   APAF1↑, 1,   Apoptosis↑, 14,   ASK1↑, 1,   BAD↑, 2,   Bak↑, 2,   BAX↑, 10,   Bax:Bcl2↑, 3,   Bcl-2↓, 8,   Bcl-xL↓, 3,   BMP2↓, 1,   Casp↑, 3,   Casp1↓, 1,   Casp3↑, 13,   cl‑Casp3↑, 1,   Casp6↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 5,   cl‑Casp9↑, 1,   proCasp9↓, 1,   Cyt‑c↑, 4,   Cyt‑c↝, 1,   DR5↑, 4,   Fas↑, 3,   FasL↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 3,   iNOS↓, 3,   JNK↑, 5,   p‑JNK↑, 1,   MAPK↓, 3,   MAPK↑, 4,   Mcl-1↓, 2,   MDM2↓, 2,   p‑MDM2↓, 1,   Necroptosis↑, 1,   necrosis↑, 1,   NICD↓, 1,   p27↑, 5,   p38↓, 2,   p38↑, 1,   p‑p38↑, 2,   survivin↓, 5,   Telomerase↓, 3,   TRAIL↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

H3↓, 1,   H4↓, 1,   KISS1↑, 1,   other?, 1,   other↑, 1,   Prot↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 3,   GRP78/BiP↓, 1,   HSP27↑, 1,   HSP90↓, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   BNIP3↑, 1,   LC3B-II↑, 1,   LC3II↑, 2,   p62↓, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

DNAdam↑, 4,   DNArepair↓, 1,   DNArepair↑, 2,   P53↑, 8,   PARP↑, 2,   cl‑PARP↑, 1,   PCNA↓, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 6,   CDK4↓, 4,   cycA1/CCNA1↓, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 5,   P21↑, 7,   TumCCA↑, 15,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 1,   CD34↓, 1,   cFos↑, 1,   CSCs↓, 3,   Diff↑, 1,   EMT↓, 6,   EMT↑, 1,   ERK↓, 4,   ERK↑, 1,   p‑ERK↓, 2,   p‑ERK↑, 1,   FOXO3↓, 3,   GSK‐3β↓, 3,   p‑GSK‐3β↓, 1,   HDAC↓, 5,   HDAC2↓, 1,   HDAC3↓, 1,   IGF-1?, 1,   IGF-1↓, 3,   IGF-1R↓, 2,   IGFBP3↑, 1,   mTOR↓, 4,   p‑mTOR↓, 1,   NOTCH↓, 1,   NOTCH1↓, 2,   P70S6K↓, 1,   PI3K↓, 5,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 3,   p‑PTEN↓, 1,   PTPN6↑, 1,   RAS↓, 2,   p‑Src↓, 1,   STAT↓, 1,   STAT3↓, 6,   p‑STAT3↓, 2,   STAT5↓, 1,   p‑STAT6↓, 1,   TAZ↓, 1,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 3,   TumCG↑, 1,   VGCC↑, 1,   Wnt↓, 2,  

Migration ⓘ

AEG1↓, 1,   AntiAg↑, 1,   AXL↓, 1,   Brk/PTK6↓, 1,   CA↓, 1,   Ca+2↑, 5,   Ca+2↝, 1,   CD31↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 5,   F-actin↓, 1,   FAK↓, 4,   p‑FAK↑, 1,   ITGB1↓, 1,   MALAT1↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 11,   MMP7↓, 3,   MMP9↓, 13,   MMPs↓, 3,   N-cadherin↓, 4,   PAK1↓, 1,   PDGF↓, 1,   PKCδ↓, 1,   Rac1↓, 1,   Rho↓, 1,   Slug↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TIMP1↑, 3,   TIMP2↑, 3,   Treg lymp↓, 1,   TSP-1↑, 1,   TumCA↓, 1,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 13,   TumMeta↓, 3,   TumMeta↑, 1,   Twist↓, 3,   Tyro3↓, 1,   uPA↓, 1,   VCAM-1↓, 1,   Vim↓, 5,   Vim↑, 1,   ZO-1↑, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 4,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 11,   angioG↑, 1,   EGFR↓, 2,   EGFR↑, 1,   p‑EGFR↓, 1,   Hif1a↓, 17,   LOX1↓, 1,   NO↓, 1,   NO↑, 2,   VEGF↓, 36,   VEGF↑, 1,   VEGFR2↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 1,   GLUT1↑, 1,   GLUT3↑, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   CD4+↑, 1,   COX2↓, 8,   COX2↑, 1,   CXCR4↓, 1,   FOXP3↓, 2,   ICAM-1↓, 1,   IFN-γ↓, 1,   Igs↑, 1,   IKKα↓, 1,   IL1↓, 1,   IL10↑, 3,   IL12↓, 1,   IL1β↑, 1,   IL2↑, 2,   IL4↑, 1,   IL6↓, 5,   IL8↓, 1,   Inflam↓, 1,   LIF↑, 1,   NF-kB↓, 15,   NF-kB↑, 1,   p‑NF-kB↑, 1,   NK cell↑, 2,   p65↓, 1,   p65↑, 1,   p‑p65↓, 1,   PD-1↓, 1,   PGE2↓, 1,   PSA↓, 1,   PSA∅, 1,   T-Cell↑, 1,   Th1 response↑, 1,   TLR4↓, 2,   TNF-α↓, 4,   TNF-α↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 4,   ER(estro)↓, 1,   GR↑, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioAv↝, 2,   ChemoSen↓, 1,   ChemoSen↑, 10,   CYP1A2↓, 1,   Dose?, 2,   Dose↑, 1,   Dose↝, 2,   Dose∅, 3,   eff↓, 2,   eff↑, 9,   eff↝, 3,   eff∅, 1,   Half-Life↝, 1,   Half-Life∅, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 9,   selectivity↑, 7,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 4,   AST↓, 1,   BloodF↑, 1,   CEA↓, 1,   EGFR↓, 2,   EGFR↑, 1,   p‑EGFR↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 3,   IL6↓, 5,   NSE↓, 1,   PSA↓, 1,   PSA∅, 1,  

Functional Outcomes ⓘ

AntiCan↑, 7,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 1,   chemoP↑, 4,   ChemoSideEff↓, 4,   neuroP↑, 1,   OS↑, 6,   Pin1↓, 1,   QoL↑, 1,   radioP↑, 2,   Remission↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 2,  
Total Targets: 356

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 7,   GPx↑, 2,   GPx3↑, 1,   GSH↑, 5,   GSR↑, 3,   GSTA1↑, 1,   GSTs↑, 2,   lipid-P↓, 2,   MDA↓, 2,   NRF2↑, 3,   ROS↓, 9,   ROS↑, 1,   SOD↑, 7,   SOD2↑, 1,   uricA↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   MMP↑, 1,  

Cell Death ⓘ

Akt↓, 2,   Akt↑, 2,   p‑Akt↑, 1,   Apoptosis↓, 2,   BAD↓, 1,   BAX↓, 1,   Bax:Bcl2↓, 1,   Bcl-xL↑, 1,   BMP2↑, 1,   Casp3↓, 3,   HGF/c-Met↑, 1,   iNOS↓, 1,   MAPK↑, 1,   p38↓, 1,   p38↑, 1,  

Kinase & Signal Transduction ⓘ

SOX9↑, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↑, 2,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 1,  

Cell Cycle & Senescence ⓘ

E2Fs↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

Diff↑, 2,   ERK↑, 1,   p‑ERK↑, 1,   FGF↑, 2,   MSCs↑, 1,   mTOR↓, 1,   mTOR↑, 1,   PI3K↑, 1,   STAT↓, 1,   Wnt↑, 1,  

Migration ⓘ

AntiAg↑, 1,   Ca+2↓, 1,   Ca+2↑, 4,   Cartilage↑, 2,   COL2A1↑, 1,   FAK↑, 1,   ITGB1↑, 1,   MMP2↓, 1,   MMP2↑, 1,   MMP9↓, 2,   MMP9↑, 1,   MMPs↑, 1,   PDGF↑, 1,   PKA↑, 1,   PKCδ↓, 1,   Rac1↑, 1,   SMAD4↑, 1,   SMAD5↑, 1,   TGF-β↑, 2,   TIMP1↑, 1,   TIMP2↑, 1,   uPA↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   angioG↑, 3,   angioG↝, 1,   HIF-1↓, 1,   Hif1a↑, 2,   Hif1a∅, 1,   NO↓, 4,   NO↑, 1,   VEGF↓, 2,   VEGF↑, 12,   VEGFR2↑, 1,  

Barriers & Transport ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1↓, 2,   IL1↑, 1,   IL10↑, 3,   IL12↓, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 3,   Inflam↓, 9,   NF-kB↓, 3,   PGE2↓, 1,   PGE2↑, 1,   TNF-α↓, 4,   TNF-α↑, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 2,  

Protein Aggregation ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 1,   Dose↝, 2,   eff↓, 1,   eff↑, 7,   Half-Life↝, 2,  

Clinical Biomarkers ⓘ

BMPs↓, 1,   IL6↓, 3,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 1,   memory↑, 1,   motorD↑, 1,   neuroP↑, 2,   Pain↓, 2,   QoL↑, 1,   radioP↑, 1,   toxicity↓, 2,   toxicity∅, 3,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 121

Scientific Paper Hit Count for: VEGF, Vascular endothelial growth factor
16 Thymoquinone
15 Apigenin (mainly Parsley)
14 Magnetic Fields
12 EGCG (Epigallocatechin Gallate)
11 Betulinic acid
11 Sulforaphane (mainly Broccoli)
10 Resveratrol
10 Quercetin
9 Baicalein
9 Berberine
9 Curcumin
8 Propolis -bee glue
8 Chrysin
7 Silver-NanoParticles
7 Artemisinin
7 Boswellia (frankincense)
7 Fisetin
7 Silymarin (Milk Thistle) silibinin
6 Garcinol
5 Radiotherapy/Radiation
5 Chlorogenic acid
5 Ellagic acid
5 Honokiol
4 Ashwagandha(Withaferin A)
4 Caffeic acid
4 Deguelin
4 Luteolin
4 Phenethyl isothiocyanate
3 Alpha-Lipoic-Acid
3 Cisplatin
3 Bevacizumab (brand Avastin)
3 Boron
3 Capsaicin
3 Carvacrol
3 Cinnamon
3 Emodin
3 Fucoidan
3 Ferulic acid
3 Hydrogen Gas
3 Juglone
3 Lycopene
3 Magnolol
3 Melatonin
3 Naringin
3 Piperine
3 Selenite (Sodium)
2 Biochanin A
2 Chemotherapy
2 Thymol-Thymus vulgaris
2 Celecoxib
2 Celastrol
2 Ursolic acid
2 Gambogic Acid
2 Gemcitabine (Gemzar)
2 Ginger/6-Shogaol/Gingerol
2 Proanthocyanidins
2 Hydroxycinnamic-acid
2 HydroxyTyrosol
2 Methylsulfonylmethane
2 Phenylbutyrate
2 Piperlongumine
2 Rosmarinic acid
2 Shikonin
2 Vitamin C (Ascorbic Acid)
1 Auranofin
1 Astragalus
1 Allicin (mainly Garlic)
1 alpha Linolenic acid
1 Andrographis
1 Ascorbyl Palmitate
1 Astaxanthin
1 Aloe anthraquinones
1 beta-glucans
1 immunotherapy
1 Baicalin
1 Berbamine
1 Bufalin/Huachansu
1 Brucea javanica
1 brusatol
1 Caffeic Acid Phenethyl Ester (CAPE)
1 chitosan
1 Coenzyme Q10
1 Vitamin E
1 Docetaxel
1 Gallic acid
1 Paclitaxel
1 Genistein (soy isoflavone)
1 Ginseng
1 γ-linolenic acid (Borage Oil)
1 Graviola
1 Grapeseed extract
1 itraconazole
1 mebendazole
1 metronomic chemo
1 Mushroom Shiitake, AHCC
1 Myricetin
1 Niclosamide (Niclocide)
1 Oleuropein
1 Plumbagin
1 VitK3,menadione
1 Psoralidin
1 Pterostilbene
1 Kaempferol
1 salinomycin
1 Sanguinarine
1 Salvia miltiorrhiza
1 Theobromine
1 Aflavin-3,3′-digallate
1 Urolithin
1 Vitamin D3
1 Zinc
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:334  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page